# MaxCyte and TG Therapeutics partner on next-gen cell therapy for MS

- Link: https://www.directorstalkinterviews.com/maxcyte-and-tg-therapeutics-partner-on-next-gen-cell-therapy-for-ms/4121186182
- Published: 2025-02-12T07:23:10+00:00
- Author: Amilia Stone

**MaxCyte, Inc.**, (Nasdaq: MXCT; LON:MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics, has announced 
they are entering into a strategic platform license (SPL) with TG Therapeutics, 
a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition,
development and commercialization of novel treatments for B-cell diseases.

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research,
clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology
and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing
fees and program-related revenue.

TG Therapeutics entered into an agreement with Precision BioSciences, Inc. and acquired
a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an investigational
allogeneic or “off the shelf” CD19 CAR T cell therapy program for autoimmune diseases
and all other non-oncology indications. TG received clearance by the U.S. Food and
Drug Administration (FDA) of an Investigational New Drug (IND) application for azer-
cel in progressive forms of multiple sclerosis (MS) and is targeting commencement
of a Phase 1 trial in 2025.

> “By leveraging our commercially validated cell-engineering platform and optimized
> T cell manufacturing workflow, TG Therapeutics is advancing toward their Phase
> 1 clinical trial for the application of azer-cel in progressive forms of MS,” 
> said **Maher Masoud, President and CEO of MaxCyte**. “Our technology has been 
> integral to the manufacturing of allogeneic T cell immunotherapies and was efficiently
> transferred from Precision BioSciences when TG Therapeutics obtained global rights
> for azer-cel for autoimmune diseases in January 2024. With our new partnership,
> we will continue to support the development of azer-cel to expand the application
> to autoimmune diseases.”

MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically
and commercially validated electroporation technology for complex and scalable cell
engineering. By delivering high transfection efficiency and cell viability, seamless
scalability and enhanced functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and cellular therapeutics.

Share on:
